10月14日 - ** Vir Biotechnology（VIR.O）股价在盘前交易中上涨11.7%，至11.85美元
** 该公司与吉利德（GILD.O）就三款针对特定实体瘤相关抗原的候选药物签署了合作与许可协议
** VIR 有资格获得总额高达 1.35 亿美元的预付款和近期临床前里程碑付款，并有望获得最高 17.4 亿美元的后续里程碑付款，以及基于净销售额的分级特许权使用费
** VIR负责药物发现、设计和优化，而吉利德将获得基于VIR平台开发的这三种T细胞结合剂的独家开发和商业化许可
** T细胞结合剂是强效的抗肿瘤药物，旨在引导免疫系统摧毁癌细胞
** 此外，双方还签署了一项股票购买协议，根据该协议，GILD将以每股14.16美元的价格购买约177万股VIR股票，总投资额约为2500万美元
** 截至上一交易日收盘，VIR股票今年以来累计上涨约76%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.